Kirchner Margaret, Palacios Alexandra, Cataldo Natalie, Allen Kate L, Wellman Allison, Madad Asma, Jemaneh Temesgen, Jackson Timothy, Ingram David T, Wagoner Victoria, Hatch Robert, Baugher Joseph, Burall Laurel, Nieves Kenneth, Low Mabel, Pederson Grace, DiPrete Lauren, Sepcic Victoria, Thomas Deepam, Lozinak Kristen, Urban Sinisa, Shannon Kyle, Kafka Erin, Lackey Ainsley, Edwards Lauren, Rosen Hilary E, Bond Christian, Needham Michael, Locas Annie, Markell Austin, Chau Kelvin, Kong Adrienne, Hamel Meghan, Kearney Ashley, Salter Monique, Gieraltowski Laura, Bazaco Michael C, Viazis Stelios, Conrad Amanda
Food and Drug Administration, College Park, MD, USA.
Centers for Disease Control and Prevention, Atlanta, GA, USA.
J Food Prot. 2025 Jan 2;88(1):100413. doi: 10.1016/j.jfp.2024.100413. Epub 2024 Nov 20.
In 2022, the U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), U.S. state and local partners, the Public Health Agency of Canada (PHAC), and the Canadian Food Inspection Agency (CFIA) conducted a binational sample-initiated retrospective outbreak investigation (SIROI) of Listeria monocytogenes illnesses linked to enoki mushrooms. The FDA and CDC investigated the first known L. monocytogenes outbreak linked to enoki mushrooms from 2016 to 2020, making the 2022 outbreak the second time this pathogen-commodity pair was investigated by FDA and CDC. The 2022 outbreak included six ill people, all of whom were hospitalized. Epidemiologic, laboratory, and traceback evidence led to multiple public health actions, including voluntary recalls by firms, public communications about the outbreak, and FDA's country-wide Import Alert for enoki mushrooms from China. This SIROI illustrates the importance of surveillance sampling, national and international coordination of efforts, and rapid information sharing to identify and stop foodborne outbreaks on a global scale. To reduce the risk of listeriosis illnesses linked to contaminated enoki mushrooms, public health and regulatory agencies in the United States and Canada remain committed to conducting comprehensive surveillance for Listeria in foods and in people, efficiently investigating identified outbreaks, and implementing control measures to potentially minimize the impact of future outbreaks.
2022年，美国食品药品监督管理局（FDA）、疾病控制与预防中心（CDC）、美国州和地方合作伙伴、加拿大公共卫生署（PHAC）以及加拿大食品检验局（CFIA）对一起与金针菇相关的单核细胞增生李斯特菌病进行了双边样本启动的回顾性疫情调查（SIROI）。FDA和CDC对2016年至2020年期间首次已知的与金针菇相关的单核细胞增生李斯特菌疫情进行了调查，这使得2022年的疫情成为FDA和CDC对这一致病菌-商品组合的第二次调查。2022年的疫情涉及6名患者，他们均住院治疗。流行病学、实验室和追溯证据引发了多项公共卫生行动，包括企业自愿召回、关于疫情的公众通报，以及FDA针对来自中国的金针菇发布的全国性进口警示。此次SIROI表明了监测采样、国家和国际层面的协调努力以及快速信息共享对于在全球范围内识别和阻止食源性疫情的重要性。为降低与受污染金针菇相关的李斯特菌病风险，美国和加拿大的公共卫生及监管机构仍致力于对食品和人群中的李斯特菌进行全面监测，高效调查已确认的疫情，并实施控制措施以尽可能降低未来疫情的影响。
